Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

43.19
BATS BZX Real-Time Price
As of 2:42pm ET
 +0.16 / +0.37%
Today’s Change
37.59
Today|||52-Week Range
55.51
-20.12%
Year-to-Date
How EpiPen came to symbolize corporate greed
1:57pm / CNNMoney.com
Trader's Daily Notebook: Is It Worth Trying to Catch a Bottom in Biotechs?
Aug 26 / TheStreet.com - Paid Partner Content
Mylan Promises $300 Generic EpiPen
1:39pm / Zacks.com - Paid Partner Content
5 Things You Must Know Before the Market Opens Friday
Aug 26 / TheStreet.com - Paid Partner Content
5 Winning Stocks That Could Be Ready to Drop
12:29pm / TheStreet.com - Paid Partner Content
Cramer: Getting to the Heart -- or the Lack of It -- of the EpiPen Issue
Aug 25 / TheStreet.com - Paid Partner Content
Lee Ainslie's Top 3 New Holdings
12:11pm / GuruFocus News - Paid Partner Content
Tone-Deaf Mylan Provides Election-Year Fodder
Aug 25 / MotleyFool.com - Paid Partner Content
Stocks Post Strong Gains as Wall Street Weighs Prospects for a Rates Boost
11:33am / TheStreet.com - Paid Partner Content
Mylan (MYL) CEO Heather Bresch Needs To Explain EpiPen Price Hike, Senator Grassley T...
Aug 25 / TheStreet.com - Paid Partner Content
Mylan (MYL) To Offer Cheaper EpiPen Option, BloombergTV Weighs In
11:14am / TheStreet.com - Paid Partner Content
Wall Street Hesitates Ahead of Yellen's Speech on Friday
Aug 25 / TheStreet.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSp...
10:50am / Zacks.com - Paid Partner Content
As Predictable As the Sun Rising
Aug 25 / TheStreet.com - Paid Partner Content
More Squawk From Jim Cramer: Mylan (MYL) Became a Monopoly
10:29am / TheStreet.com - Paid Partner Content
Mylan's EpiPen Price Increase Is a Reason to Stay Clear of the Company
Aug 25 / TheStreet.com - Paid Partner Content
Mylan to launch cut-price generic version of EpiPen
10:09am / FT.com - Paid Partner Content
Top Research Reports for August 25, 2016
Aug 25 / Zacks.com - Paid Partner Content
Does Mylan Really Need to Charge $614.07 for EpiPens?
10:06am / MotleyFool.com - Paid Partner Content
Mylan (MYL) Listens to Critics, Will Make EpiPen More Affordable
Aug 25 / Zacks.com - Paid Partner Content
Stocks Extend Gains as Wall Street Mulls Possible Rate Hike
9:49am / TheStreet.com - Paid Partner Content
Mylan: pen is not mightier
Aug 25 / FT.com - Paid Partner Content
Generic EpiPen coming for $300, as Mylan responds to outrage
8:43am / CNNMoney.com
Mylan EpiPen Scrutiny Puts More Biotechs at Risk
Aug 25 / TheStreet.com - Paid Partner Content
Morning Movers: HLF, MYL, WLL, HOG
8:41am / TheStreet.com - Paid Partner Content
Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny
Aug 25 / TheStreet.com - Paid Partner Content
Stock Futures Flat as Investors Weigh Possible Rate Hike
7:55am / TheStreet.com - Paid Partner Content
More Squawk from Jim Cramer: Mylan (MYL) Should Have More Competition
Aug 25 / TheStreet.com - Paid Partner Content
Mylan to Launch Cheaper Generic Alternative to EpiPen; Shares Rise
7:09am / TheStreet.com - Paid Partner Content
Why Mylan's EpiPen Is Sparking "Epi-Rage"
Aug 25 / MotleyFool.com - Paid Partner Content
Pharma Has History of Price Gouging, Mylan Should Be No Surprise
Aug 26 / TheStreet.com - Paid Partner Content
Mylan EpiPen Controversy Puts More Biotechs in Danger
Aug 25 / TheStreet.com - Paid Partner Content
Black Rock Pharmacy Co-Owner Arthur To CNBC: 'There's a Huge Issue With PBMs'
Aug 26 / TheStreet.com - Paid Partner Content
Stock Market News for August 25, 2016
Aug 25 / Zacks.com - Paid Partner Content
Forget Mylan, Buy These 3 Drug Stocks Instead
Aug 26 / Zacks.com - Paid Partner Content
'No One Is More Frustrated Than Me,' Mylan (MYL) CEO Heather Bresch Tells CNBC
Aug 25 / TheStreet.com - Paid Partner Content
Pharmacy Benefit Managers Shouldn't Fret Initial Fallout from Mylan Fiasco
Aug 26 / TheStreet.com - Paid Partner Content
EpiPen CEO: Blame the 'broken' system, not me
Aug 25 / CNNMoney.com
Is the "Internet of Things" a Fad or the Future?
Aug 26 / Zacks.com - Paid Partner Content
Mylan Is Done Leaning on EpiPen Sales and That Could be a Big Problem
Aug 25 / TheStreet.com - Paid Partner Content
EpiPen outrage may fuel cheap generic in 2017
Aug 26 / CNNMoney.com
Mylan bends to backlash with drug discount
Aug 25 / FT.com - Paid Partner Content
Biotech ETFs in Focus After Mylan's EpiPen Controversy
Aug 26 / Zacks.com - Paid Partner Content
Mylan Dispute Puts More Biotechs in Danger
Aug 25 / TheStreet.com - Paid Partner Content
Stock Market News for August 26, 2016
Aug 26 / Zacks.com - Paid Partner Content
Mylan (MYL) Obtains Favorable USPTO Ruling for Copaxone
Aug 25 / Zacks.com - Paid Partner Content
Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
Aug 26 / Zacks.com - Paid Partner Content
Mallinckrodt's Top Drug Could Go the Way of EpiPen
Aug 25 / TheStreet.com - Paid Partner Content
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Blackstone Group, Mylan, Lululemo...
Aug 26 / Zacks.com - Paid Partner Content
Mylan pledges to make EpiPen more affordable
Aug 25 / CNNMoney.com